MEI Pharma Chooses Litecoin As Treasury Asset, Begins With $100 Million LTC Purchase

MEI Pharma, Inc., a late-stage pharmaceutical firm that aims to develop new cancer therapies, has launched its Litecoin-based digital asset treasury. MEI Pharma announced the purchase of 929,548 LTC tokens to begin its treasury.

MEI Pharma Launches the First Litecoin Reserve With $100M Purchase

On August 5, MEI Pharma, a publicly traded pharmaceutical company listed on the NASDAQ, reported that it had purchased 929,548 Litecoin tokens for a total of $100 million. 

MEI Pharma reported having bought the tokens at an average price of $107.58 per LTC between July 30 and August 4 in the press release. The purchase was funded by a $100 million private round led by Charlie Lee, the founder of Litecoin, and crypto trading firm GSR. 

Lee was brought on board MEI Pharma’s board of directors, replacing Taheer Datoo. MEI contracted GSR to be the digital asset manager to facilitate the deal. LTC Foundation, Hivemind, ParaFi, Primitive, and RLH Capital, as well as Delta Blockchain, were all participants in the funding round.

Thanks to this acquisition, MEI Pharma has become the very first public company based in the United States to use Litecoin as the main treasury reserve asset. The Litecoin treasury was built by MEI Pharma to rely on the scalability and reliability of LTC as an enduring store of value and treasury operational asset. 

Why MEI Pharma Picked Litecoin

According to MEI Pharma, Litecoin was chosen as its preferred treasury asset for three main reasons. Firstly, Litecoin has a track record of proven reliability, running for over 13 years without any downtime. The operational efficiency of Litecoin, with its low fees and fast settlement, makes LTC an ideal digital asset for treasury and reserve allocation. 

The extensive user base and merchant network of Litecoin, along with its wide integration into platforms like BitPay, Robinhood, PayPal, and Venmo, was another reason why LTC was chosen over other cryptos. On this point, Litecoin recently emerged as the second most used crypto for payments, with a market share of 14.5% of the entire crypto industry.

MEI is evaluating an increase in its exposure to Litecoin by adding additional support in places like mining. Meanwhile, it also proceeds with its primary pharmaceutical research work.

MEI is evaluating an increase in its exposure to Litecoin by adding additional support in places like mining. The company could also commit to long-term innovation in capital structure and financial technology. Meanwhile, it also proceeds with its primary pharmaceutical research work.

MEI Pharma Takes A Different Route To Crypto Treasuries

MEI will become the latest company to add cryptocurrencies to its balance sheet. Whereas other projects have selected such assets as Bitcoin, Ethereum, or Solana, MEI decided to go in another direction and support Litecoin, a token with a solid technical history and a good industry reputation.

Commenting on the treasury launch, Charlie Lee stated that by initiating this strategy, MEI is making a clear, institutional step forward with understanding that Litecoin will play a role as both a reserve asset and a component of financial systems around the globe.